PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19724921-9	2009	Accordingly, EPHA2 expression was markedly augmented in vitro in neuroblastoma cells treated with doxorubicin, which is commonly used for treating unfavorable neuroblastoma.	Doxorubicin	98-109	EPH receptor A2	Homo sapiens	13-18	
29110283-0	2017	EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.	Doxorubicin	15-26	EPH receptor A2	Homo sapiens	0-5	
29110283-1	2017	PURPOSE: To employ Doxorubicin-loaded liposomes, modified with YSA-peptide to target EphA2, to reduce adverse effects against primary bone cells and maximize toxicity against Saos-2 osteosarcoma cells.	Doxorubicin	19-30	EPH receptor A2	Homo sapiens	85-90	
35217483-7	2022	Treatment with either doxorubicin-loaded hyperbranched polymer, or the same nanomedicine targeted to an ephrin receptor (EphA2) using a bispecific antibody, resulted in uptake of chemotherapeutic doxorubicin in the tumour and in reduced tumour growth.	Doxorubicin	196-207	EPH receptor A2	Homo sapiens	121-126	
29392452-11	2018	Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro.	Doxorubicin	48-59	EPH receptor A2	Homo sapiens	25-30	
29392452-11	2018	Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro.	Doxorubicin	78-81	EPH receptor A2	Homo sapiens	25-30